Q3 Earnings Estimate for CHRS Issued By HC Wainwright

Coherus Oncology, Inc. (NASDAQ:CHRS) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Coherus Oncology in a research report issued to clients and investors on Thursday, October 29th. HC Wainwright analyst S. Ramakanth forecasts that the biotechnology company will post earnings of ($0.22) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Coherus Oncology’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.48) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.19 EPS.

Coherus Oncology (NASDAQ:CHRS) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. The company had revenue of $14.31 million during the quarter, compared to the consensus estimate of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%.

Separately, Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Coherus Oncology presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Coherus Oncology Stock Up 7.5%

CHRS stock opened at $0.81 on Monday. The stock’s fifty day simple moving average is $1.17 and its two-hundred day simple moving average is $1.52. The company has a current ratio of 1.77, a quick ratio of 1.70 and a debt-to-equity ratio of 0.61. Coherus Oncology has a 1-year low of $0.75 and a 1-year high of $2.62. The stock has a market cap of $124.47 million, a P/E ratio of -0.78 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Spark Investment Management LLC purchased a new stake in Coherus Oncology during the 2nd quarter worth about $25,000. Jefferies Financial Group Inc. bought a new stake in shares of Coherus Oncology during the second quarter valued at about $353,000. Corient Private Wealth LP purchased a new stake in shares of Coherus Oncology in the second quarter worth about $140,000. Bank of America Corp DE bought a new position in shares of Coherus Oncology in the second quarter valued at approximately $424,000. Finally, Hsbc Holdings PLC bought a new position in shares of Coherus Oncology in the second quarter valued at approximately $131,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.